<DOC>
	<DOCNO>NCT00210639</DOCNO>
	<brief_summary>The purpose study ass long-term safety levofloxacin administer child therapy acute bacterial infection .</brief_summary>
	<brief_title>A Study Incidence Musculoskeletal Disorders Children Who Have Received Levofloxacin Standard Non-Fluoroquinolone Therapy Acute Bacterial Infection</brief_title>
	<detailed_description>This prospective ( look forward use periodic observation collect predominantly follow participant enrollment ) , long-term , comparative , multicenter , observational study ( study investigators/physicians observe participant measure outcome ) monitor long-term incidence musculoskeletal ( MS ) disorder child receive levofloxacin standard therapy acute bacterial infection . Approximately 2500 participant enrol prior Phase 3 clinical study use levofloxacin treatment acute infectious disease observe study . The study consist 3 phase : screening phase ; surveillance phase ; musculoskeletal disorder follow-up phase . Safety evaluation include assessment overall incidence musculoskeletal disorder occur first 60 day first dose anti-microbial therapy . The specific musculoskeletal disorder report : tendinopathy ( inflammation rupture tendon ) ; arthritis ( inflammation joint show redness swell ) ; arthralgia ( pain joint ) ; gait abnormality ( limp refusal walk ) . Other assessment safety include interview use standardized questionnaire assess occurrence musculoskeletal adverse event , physical examination , measurement participant height course 1 year .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Musculoskeletal Diseases</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Must take least 1 dose levofloxacin standard nonfluoroquinolone therapy part Phase 3 levofloxacin clinical study ( LOFBIVPCAP003 , LOFBOOTMD001 , LOFBOOTMD002 ) treat acute bacterial infection Parent legal guardian read sign informed consent form Participants meet criterion enrollment prior Phase 3 clinical study levofloxacin take least one dose levofloxacin standard nonfluoroquinolone therapy 1 3 prior Phase 3 levofloxacin clinical study ( LOFBIVPCAP003 , LOFBOOTMD001 , LOFBOOTMD002 )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Musculoskeletal Disorders</keyword>
	<keyword>Childhood Disease</keyword>
	<keyword>Bone Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Levofloxacin</keyword>
	<keyword>Quinolones</keyword>
	<keyword>Bacterial infection</keyword>
</DOC>